Figure. 2

The cfDNA 5hmC signature is highly sensitive for measurable residual disease detection in AML. A Boxplot of weighted-detection scores (wd-scores) in AML samples with no measurable residual disease (MRD) assessed by multiparameter flow cytometry (MFC). Black dashed line represents a cutoff score of 0.229. Center line represents median, bounds of box represent 25th and 75th percentiles, and whiskers are Tukey whiskers. B Comparison of MRD detection by the cfDNA 5hmC method and molecular methods. Molecular-, no MRD detected by molecular methods. Molecular+, MRD detected by molecular methods. The number of patients is displayed on the columns. C Kaplan–Meier analysis of relapse-free survival (RFS) of AML patients with no MRD by MFC based on the cfDNA 5hmC method. Censored patients are indicated by dots. D Timing and MRD results were assessed using the cfDNA 5hmC method for each AML patient. AML patient samples with no MRD detected by MFC are displayed. Patients were ordered by total days of clinical follow-up from registration. HSCT, hematopoietic stem cell transplant